New from old: discovery of the novel antibiotic actinomycin L in *Streptomyces* sp. MBT27

Nataliia Machushynets ^a, Somayah S. Elsayed ^a, Chao Du ^a, Maxime A. Siegler ^b, Mercedes de la Cruz ^c, Olga Genilloud ^c, Thomas Hankemeier ^d and Gilles P. van Wezel ^{a, #}

^a *Molecular Biotechnology, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, The Netherlands*

^b *Department of Chemistry, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States*

^c *Fundación MEDINA, Health Sciences Technology Park, Avda Conocimiento 34, 18016 Granada, Spain*

^d *Leiden Academic Centre for Drug Research (LACDR), Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands*

[#] Author for correspondence. Tel: +31 71 5274310; email: g.wezel@biology.leidenuniv.nl

ABSTRACT

Streptomycetes are major producers of bioactive natural products, including the majority of the antibiotics. While much of the low-hanging fruit has been discovered, it is predicted that less than 5% of the chemical space has been mined. Here, we describe the novel actinomycins L₁ and L₂, which are produced by *Streptomyces* sp. MBT27. The molecules were discovered via metabolic analysis combined with molecular networking of cultures grown with different combinations of carbon sources. Actinomycins L₁ and L₂ are diastereoisomers, and the structure of actinomycin L₂ was resolved using NMR and single crystal X-ray crystallography. Actinomycin L is formed via a unique spirolinkage of anthranilamide to the 4-oxoproline moiety of actinomycin X₂, prior to the condensation of the actinomycin halves. Feeding anthranilamide to cultures of *Streptomyces antibioticus*, which has the same biosynthetic gene cluster as *Streptomyces* sp. MBT27 but only produces actinomycin X₂, resulted in the production of actinomycin L. This shows that actinomycin L results from joining two distinct metabolic pathways, namely those for actinomycin X₂ and for anthranilamide. Actinomycins L₁ and L₂ showed significant antimicrobial activity against Gram-positive bacteria. Our work shows how new molecules can still be identified even in the oldest of natural product families.

IMPORTANCE

Actinomycin was the first antibiotic discovered in an actinobacterium by Selman Waksman and colleagues, as early as 1940. This period essentially marks the start of the ‘golden era’ of antibiotic discovery. Over time, emerging antimicrobial resistance (AMR) and the declining success rate of antibiotic discovery resulted in the current antibiotic crisis. We surprisingly discovered that under some growth conditions, *Streptomyces* sp. MBT27 can produce actinomycins that are significantly different from those that have been published so far. The impact of this work is not only that we have discovered a novel molecule with very interesting chemical modifications in one of the oldest antibiotics ever described, but also that this requires the combined action of primary and

secondary metabolic pathways, namely the biosynthesis of anthranilamide and of actinomycin X₂, respectively. The implication of the discovery is that even the most well-studied families of natural products may still have surprises in store for us.

Keywords: actinomycin, *Streptomyces*, OSMAC, GNPS molecular networking, antibiotics

INTRODUCTION

Considering the emerging crisis of antibiotic resistance that spreads among bacterial pathogens and increasing incidence of cancer, the search for new, efficient and less toxic drugs remains a priority (46, 56). Actinobacteria have been the source for the majority of the antibiotics in use today (2, 4). Of the Actinobacteria, members of the genus *Streptomyces* produce over half of all currently characterized antibiotics. Genome sequencing revealed that Actinobacteria have much more biosynthetic potential to produce bioactive molecules than originally anticipated, with even the model organisms harbouring many so-called cryptic or silent biosynthetic gene clusters (BGCs) that specify yet unknown compounds (3, 14, 23). Triggering the expression of silent BGCs by genetic and cultivation-based techniques should facilitate unlocking this yet unexplored chemical diversity, allowing the discovery of novel molecules (40, 49). This strategy relies on altering the regulatory networks of the producing organism in response to fluctuating culturing conditions, such as carbon, nitrogen or phosphate concentration (41, 48, 50). Manipulation of fermentation conditions of promising producer strains, known as "one strain many compounds" (OSMAC) approach, is effective in enhancing secondary metabolites production (7, 38). Novel secondary metabolites have been discovered via modification of cultivation parameters, including nutrients (60, 61), and addition of chemical elicitors (11, 37).

Metabolic profiling of crude extracts obtained under different growth conditions represents a challenging analytical task since these mixtures are composed of hundreds of natural products.

Therefore, metabolomics, particularly those based on mass spectrometry (MS), became more and more valuable and greatly increased the efficiency of such screenings. Supervised statistical methods are able to classify a response like a biological activity, and to determine the most discriminant metabolite(s) related to such response (57). Moreover, simultaneous dereplication of differentially expressed compounds is implemented into the drug-discovery pipelines in order to avoid rediscovery of already known compounds (18). MS-based metabolomics provides important information on the distribution of the metabolites that are present in complex mixtures, but the identification of their structures is complicated. For this purpose, the Global Natural Products Social Molecular Networking (GNPS) platform was developed, applying both molecular networking and automated searches of tandem mass spectrometry (MS/MS) fragmentation spectra against spectral libraries, to identify structural relationships between metabolites (34, 53). This greatly facilitates the annotation and dereplication of known molecules.

Actinomycin is a DNA-targeting antibiotic and anticancer compound discovered in 1940 by Waksman & Woodruff, and in fact the first antibiotic that was isolated from an actinobacterium (52). Actinomycins are produced by various *Streptomyces* strains and are composed of a chromophore group and two pentapeptide chains with a variable composition of amino acids (25). Actinomycins D, X_{0β} and X₂ are usually simultaneously produced and differ from each other by substitutions on the “proline” residue in their pentapeptide lactone rings, while members of the actinomycin C complex vary in their “D-valine” residues (12). The pentapeptide precursors are biosynthesized by a non-ribosomal peptide synthetase (NRPS) assembly line, and actinomycins are formed through oxidative condensation of two 3-hydroxy-4-methylantranilic acid (4-MHA) pentapeptide lactones (PPLs) (13).

In this work we report the discovery of new actinomycin analogues, actinomycin L₁ and L₂, from the extracts of *Streptomyces* sp. MBT27. Multivariate data analysis combined with molecular networking indicated that the antimicrobial activity of the extracts correlated with novel actinomycins L₁ and L₂ and known actinomycins D, X_{0β} and X₂. NMR and single crystal X-ray

96 crystallography revealed that an anthranilamide moiety was spiro-linked to a proline residue in the
97 structure of actinomycins L₁ and L₂. Such a structural feature has not previously been identified in
98 naturally occurring actinomycins.

99

RESULTS

The influence of carbon sources on bioactivity and actinomycin production

Streptomyces sp. MBT27 is a gifted natural product producer that was isolated from Qinling mountains in China, with potent antibacterial activity against various MDR (multidrug-resistant) bacteria (62). We previously showed that the strain among others produces the novel quinazolinones A and B (32). To investigate the antibiotic activity of *Streptomyces* sp. MBT27 the strain was fermented in minimal medium (MM) with either of the following carbon sources (percentages in w/v): 1% of both mannitol and glycerol, 1% mannitol, 2% mannitol, 1% glycerol, 2% glycerol, 1% glucose, 2% glucose, 1% fructose, 1% arabinose, or 1% *N*-acetylglucosamine (GlcNAc). Supernatants of *Streptomyces* sp. MBT27 cultures were extracted with ethyl acetate and bioactivity assays were performed against *Bacillus subtilis* 168. Interestingly, the carbon sources had a huge effect on the antimicrobial activity (Figure S1). Particularly strong antimicrobial activity was observed when the culture medium was supplemented with glycerol + mannitol, glucose 1%, glycerol, fructose or GlcNAc; as compared to when mannitol or arabinose were used as the carbon sources.

In order to investigate the metabolic differences due to nutritional supplementation and correlate that to the antimicrobial activity, LC-MS-based metabolomics was performed. Initially, the LC-MS data were explored by unsupervised Principal Component Analysis (PCA). The first two PCs accounted for 37% and 16%, respectively, of the total data variation. PCA analysis failed to show significant metabolic separation in relation to the observed bioactivity (Figure 1A). The supervised Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA) was then applied to discriminate the samples based on their ability to inhibit *B. subtilis* (Figure 1B). The cross-validation metrics of the model ($R^2Y = 0.748$ and $Q^2Y = 0.676$) indicated that the model has a good reliability and ability of prediction. A permutation test was performed ($n = 100$) and the resulting R^2Y and Q^2Y values were significantly lower (p values < 0.01 for both), which indicated

that there was no overfitting in the model (10) (Figure S2). The OPLS-DA loadings S-plot revealed the most discriminative features between active and inactive groups (Figure 1C).

The mass features that correlated best to the bioactivity were m/z 1387.6706 (8.8 min), m/z 1255.6353 (8.53 min), m/z 1277.6175 (8.52 min), m/z 1271.651 (7.56 min) and m/z 1293.612 (7.56 min) (Figure 1C). Dereplication of those features was performed through comparison of the UV spectra, accurate masses, isotope distribution and fragmentation patterns obtained in MS/MS analysis against the chemistry databases Reaxys, ChemSpider, and the microbial natural products database Antibase (30). This allowed us to annotate the mass features with m/z 1255.6353 and 1277.6175 as the $[M+H]^+$ and $[M+Na]^+$ adduct ions of actinomycin D, respectively, while the mass features with m/z 1271.651 and 1293.612 were annotated as $[M+H]^+$ and $[M+Na]^+$ adduct ions of actinomycin $X_{0\beta}$, respectively (13). However, the mass feature with an m/z value of 1387.6706 $[M+H]^+$ could not be matched to any of the previously reported microbial natural products.

Global Natural Product Social (GNPS) molecular networking (53) was subsequently employed to detect MS/MS-based structural relatedness among molecules in an automated manner. The web-based platform generates a molecular network wherein molecules with related scaffolds cluster together. Cytoscape 3.7.2 was used for visualization of the generated molecular networks (45). A network representing the ions detected in the crude extract of *Streptomyces* sp. MBT27 grown with 1% glycerol was constructed, revealing 172 nodes clustered in 10 spectral families (Figure 2). The molecular network revealed an actinomycin spectral family containing actinomycin D, X_2 and $X_{0\beta}$. Moreover, the same spectral family included a yet unidentified compound with m/z 1387.67. It was closely connected (cosine score > 0.7) to the known actinomycins, suggesting that the molecule was a novel actinomycin. Statistical analysis showed that the extracts with stronger antimicrobial activity contained higher concentrations of actinomycins X_2 , $X_{0\beta}$, D and the new compound, in comparison with the less active ones (ANOVA,

$p < 0.05$; Figure 2). It is important to note that actinomycins were only detected in the bioactive fractions.

Large scale fermentation and NMR

To allow identification and structural analysis of the likely novel actinomycin analogue, we performed large-scale fermentation of *Streptomyces* sp. MBT27 followed by bioactivity guided fractionation. The purification process resulted in the isolation of two compounds (**1**) and (**2**), with the same mass (Figure S3 & S4). The NMR spectra of the two compounds were very similar, suggesting that they were diastereoisomers (Figure S5-S11). Based on 1D and 2D NMR analysis of **1**, together with the molecular formula and degrees of unsaturation dictated by the accurate mass, the structure of the isolated diastereoisomers was determined as a variant of actinomycin D, whereby an anthranilamide moiety had been attached through an aminal bond to the γ carbon of one of the proline residues, (Figure 3). The prolyl substitution position is the same as that of the hydroxyl and keto groups in actinomycins $X_{0\beta}$ and X_2 , respectively. The new actinomycin analogue was designated actinomycin L (with L standing for Leiden, the city of its discovery).

One of the isomers (**2**) was crystallized successfully. Single-crystal X-ray diffraction (Table S1) confirmed the structure obtained from NMR, and established the absolute configuration to be $2'S, 2''S, 4'R, 4''R, 10'R, 12'S, 12''S, 18'S, 18''S, 23'R, 23''R$ by anomalous-dispersion effects in diffraction measurements on the crystal (Figure 4). As the absolute configuration of the amino acid residues in **2** was consistent with that of previously reported actinomycins (54), and considering that the two isomers stemmed from the aminal formation at C-10', compound **1** is inevitably the 10'S isomer of actinomycin L.

Biosynthesis of actinomycin L

Actinomycins D (or X_1), X_2 , and $X_{0\beta}$ detected in the extracts of *Streptomyces* sp. MBT27 are members of the actinomycin X complex. Recently it was shown that actinomycins $X_{0\beta}$ and X_2 are

formed through the sequential oxidation of the γ -prolyl carbon by the cytochrome P450 enzyme saAcmM (31, 43). Based on its structure, actinomycin L is most likely formed through an amination reaction between the two amino groups of anthranilamide and the γ -keto group on the proline residue of actinomycin X₂. Accordingly, its production should be arrested when one of the precursors is not available. Interestingly, *Streptomyces* sp. MBT27 produced actinomycin L in very low amounts when grown with fructose (1% w/v) as the sole carbon source. Moreover, ANOVA statistical analysis showed that anthranilamide was produced in equally low amounts under the same growth conditions (ANOVA, $p < 0.05$; Figure 5). Under conditions where *Streptomyces* sp. MBT27 produced actinomycin L, namely when grown in MM with 1% GlcNAc, 1% glucose, 1% glycerol, 2% glycerol or in 1% mannitol + 1% glycerol, the strain invariably produced both actinomycin X₂ and anthranilamide. However, under conditions where actinomycin X₂ was produced but not anthranilamide, the strain failed to produce actinomycin L (Figure 5).

We therefore wondered if anthranilamide may be a precursor for the biosynthesis of actinomycin L. To test this hypothesis, we performed a feeding experiment, whereby anthranilamide was added to cultures of *Streptomyces* sp. MBT27 grown in MM with 1% fructose, where virtually no actinomycin L was produced. Analysis of the supernatant of the cultures via LC-MS revealed that actinomycin L was readily produced when anthranilamide was added, but not without it (Figure 6A). This strongly suggested that anthranilamide is required for the production of actinomycin L. However, extracts of *Streptomyces* sp. MBT27 fermented with 1% fructose and additional anthranilic acid contained both anthranilamide and actinomycin L (Figure 6A). This suggests that indeed anthranilic acid is converted into anthranilamide, which in turn is incorporated into actinomycin L.

In order to unambiguously verify that actinomycin L was the product of anthranilamide and actinomycin X₂, we conducted another biotransformation experiment, now feeding anthranilamide to *S. antibioticus* IMRU 3720, which is a known producer of actinomycins X₂ and X_{0β}, but fails to produce actinomycin L under any condition tested. In line with our hypothesis, *S. antibioticus* IMRU

3720 also failed to produce anthranilamide under any of the growth conditions (Figure S16). Excitingly, LC-MS analysis revealed the production of actinomycin L by *S. antibioticus* IMRU 3720 when anthranilamide was fed to the cultures, but never without anthranilamide (Figure 6B). This validates the concept that anthranilamide is a key precursor of actinomycin L. Conversely, when anthranilic acid instead of anthranilamide was added to cultures of *S. antibioticus* IMRU 3720, we failed to detect actinomycin L and anthranilamide (Figure 6B).

The oxidation of the proline residue in actinomycins $X_{0\beta}$ and X_2 occurs following the formation of the two halves of actinomycin, known as 4-MHA PPLs, and prior to the condensation of these halves to form actinomycin (43). Taking this into account we reasoned that anthranilamide should be incorporated into the actinomycin halves prior to condensation. To check this, 3-hydroxy-4-methylbenzoic acid (4-MHB) was added to cultures of *Streptomyces* sp. MBT27 and of *S. antibioticus* IMRU 3720. 4-MHB is a structural analogue of 4-MHA that replaces 4-MHA as a starter unit in the nonribosomal assembly of the actinomycin halves (43). When 4-MHB replaces 4-MHA, 4-MHB containing PPLs accumulate, because they cannot react with each other to give a phenoxazinone ring, as is the case with 4-MHA PPLs (27). LC-MS analysis of the 4-MHB-supplemented extracts showed the appearance of the previously reported 4-MHB-containing pentapeptide lactones PPL 1, PPL 0, and PPL 2, and new PPL, designated as PPL 3 (Figure S17-20, Table S2). The exact mass and fragmentation pattern of PPL 3 was consistent with a 4-MHB containing PPL wherein an anthranilamide moiety had been attached to the proline residue (Figure S20).

Taken together, the feeding experiments convincingly show that actinomycin L is formed through reaction of anthranilamide with the 4-keto group on the proline residue in the pentapeptide lactone. Moreover, results of the feeding experiments with 3-hydroxy-4-methylbenzoic acid show that this reaction occurs prior to the condensation of the pentapeptide lactones into actinomycin L (Figure 7).

Identification of the actinomycin BGC in *Streptomyces* sp. MBT27

To characterize the BGC responsible for actinomycin biosynthesis and compare the genes with those found in known actinomycin BGCs, *Streptomyces* sp. MBT27 was sequenced using the PacBio platform. Assembly of the PacBio reads resulted in two contigs of 8.4 Mb and 0.13 Mb in length. Analysis using AntiSMASH 6 (6) readily identified the actinomycin BGC in the 8.4 Mb contig. Comparison to the actinomycin X₂ BGC from *S. antibioticus* showed that all genes were highly conserved between the two clusters (Table S3 and Fig. S21). This strongly suggests that the actinomycin BGC does not specify the observed modifications in the actinomycin structure, and is not responsible for the production of anthranilamide. We have not yet identified the enzyme for the predicted conversion of anthranilic acid to anthranilamide.

Bioactivity of isolated compounds (MIC)

Bioactivity assays were carried out for the actinomycins, to test their ability to act as antibiotics. As expected, the compounds showed selective antibacterial activity against Gram-positive pathogens, and none of the actinomycins presented any activity against *E. coli* ATCC25922 or *K. pneumoniae* ATCC700603 (Table 2). All compounds except actinomycin X_{0B} showed antibacterial activity against Gram-positive bacteria with MIC values ranging from 1 to 16 µg/mL. Actinomycin L₁ showed somewhat higher bioactivity than actinomycin L₂, while both compounds showed slightly higher MICs than actinomycin D and Actinomycin X₂.

DISCUSSION

Actinomycin was the first antibiotic identified in Actinobacteria (52). The well-established actinomycin structure is composed of a heterocyclic chromophore and two cyclic PPLs. Biosynthetically, PPL is biosynthesized by an NRPS assembly line with the 4-MHA as the initiating unit (24, 35). 4-MHA is derived from 3-hydroxy-4-methylkynurenine (4-MHK), which is formed by

methylation of 3-hydroxykynurenine (3-HK) (12). Our work surprisingly revealed a novel structure within the extensively studied actinomycin family, namely that of actinomycin L, which arises via attachment of an anthranilamide moiety to the γ -carbon of one of the proline residues through amination formation. ANOVA statistical analysis proved that production of anthranilamide is the limiting factor in the biosynthesis of actinomycin L. Feeding experiments with anthranilamide suggested that actinomycin L is formed through the spontaneous reaction of anthranilamide with the 4-oxoproline site of actinomycin X₂ prior to the condensation of the two 4-MHA PPLs into actinomycin L. To the best of our knowledge, the attachment of anthranilamide to a 4-oxoproline moiety is a novel observation.

The actinomycin BGC of *Streptomyces* sp. MBT27 harbours the same genes as that of *S. antibioticus*, with high homology between the genes, which strongly suggests that the modification of actinomycin X₂ to actinomycin L is not encoded by the BGC itself. Indeed, we anticipate that anthranilamide is derived from anthranilic acid in *Streptomyces* sp. MBT27, whereby anthranilic acid in turn is biosynthesized through the shikimate pathway (17). Anthranilic acid is a commonly produced primary metabolite in *Streptomyces*, while anthranilamide is less common (5, 21, 44). The actinomycin X₂ producer *S. antibioticus* IMRU 3720 fails to convert anthranilic acid into anthranilamide, which explains why actinomycin L was also not detected in the extracts. However, actinomycin L was produced when we feed cultures of *S. antibioticus* IMRU 3720 with additional anthranilamide, which is fully in line with our proposed biosynthetic pathway. Thus, actinomycin L is an example of a natural product that requires the joining of two separate metabolic pathways, and this is a concept that needs more attention. After all, scientists rely increasingly on heterologous expression and synthetic biology approaches (29), and these will likely fail if genes are required that do not fall within the main BGC.

Carbon source utilization plays a major role in the control of antibiotic production (42, 50). Control of carbon utilization in streptomycetes is largely mediated via glucose kinase, via a mechanism that is still not well understood (39, 51). The pathways for antibiotic production are

subject to Glk-dependent and Glk-independent control (20). Indeed, the production of actinomycins by *Streptomyces* spp. is strongly influenced by the carbon source, whereby the preferred carbon source varies from strain to strain (16, 22, 26, 47, 55). D-galactose favors actinomycin production in *Streptomyces antibioticus* over arabinose, xylose, glucose, fructose and rhamnose (26), while glycerol was the optimal carbon source for actinomycin production by *S. antibioticus* Tü 6040 and *S. antibioticus* SR15.4 (47) (22). In the case of *Streptomyces* sp. MBT27, growth on MM with glycerol, GlcNAc, fructose and glucose (all 1% w/v) as sole carbon sources were the best carbon sources to promote the production of actinomycins. However, increasing the glucose concentration to 2% blocked the production of actinomycins. Glucose was previously reported to repress the transcription of the gene for hydroxykynureninase, which is involved in the formation of the main actinomycin precursor 4-MHA (26). Importantly, in our experiments the carbon source not only promoted the overall production levels, but also contributed to the chemical diversity of the actinomycins, including the production of actinomycin L. This coincided with the production of anthranilamide, an essential substrate to form this novel actinomycin variant.

In the 21st century, genome mining and renewed drug discovery efforts have revealed that Actinobacteria may produce many more molecules than was expected (33). What is important to note is that this also applies to well-known families of molecules and in extensively studied model organisms. Examples are the highly rearranged cryptic polyketide lugdunomycin that belongs to the family of angucyclines (59), the new glycopeptide corbomycin with a novel mode of action (15), as well as the discovery of coelimycin (19) and a novel branch of the actinorhodin biosynthetic pathway (58) in the model organism *Streptomyces coelicolor*. The discovery of actinomycin L provides another interesting example that we have not yet exhausted the known part of the chemical space. Indeed, the isolation of these novel actinomycins underlines that the biosynthetic potential of Actinobacteria still has major surprises in store, and that we can expect that new molecules can be discovered even within extensively studied microbes and compound classes.

MATERIALS AND METHODS

General Experimental Procedures

Optical rotation was recorded on MCP 100 modular circular polarimeter (Anton Paar). FT-IR spectra were recorded on IRSpirit QATR-S Fourier-transform infrared spectrophotometer (Shimadzu Corporation, Japan). UV measurements were performed using a Shimadzu UV-1700 UV-VIS spectrophotometer (Shimadzu Corporation, Japan). NMR spectra were recorded on a Bruker Ascend 850 MHz NMR spectrometer (Bruker BioSpin GmbH). The LC-ESI-MS analyses were performed using Waters Acquity UPLC system coupled to Agilent 6530 QTOF MS equipped with Agilent Jet Stream ESI source (Agilent Technologies, Inc., Palo Alto, CA, USA). The LC-ESI-MS/MS analysis was conducted using Shimadzu Nexera X2 UHPLC system, with attached PDA, coupled to Shimadzu 9030 QTOF mass spectrometer. HPLC purification was performed on Waters preparative HPLC system comprised of 1525 pump, 2707 autosampler, 2998 PDA detector, and Water fraction collector III. All organic solvents were HPLC or LC-MS grade, depending on the experiment.

Bacterial strain, growth conditions and metabolite extraction

Streptomyces sp. MBT27 was obtained from the Leiden University strain collection and had previously been isolated from the Qingling Mountains, Shanxi province, China (62). Cultures were grown in triplicate in 100 mL Erlenmeyer flasks containing 30 mL of liquid minimal medium (MM) (28), supplemented with various carbon sources, and inoculated with 10 μ L of 10⁹/mL spore suspension. The carbon sources (percentages in w/v) were: 1% mannitol + 1% glycerol, 1% mannitol, 2% mannitol, 1% glycerol, 2% glycerol, 1% glucose, 2% glucose, 1% fructose, 1% arabinose or 1% *N*-acetylglucosamine (GlcNAc). The cultures were incubated in a rotary shaker at 30 °C and 220 rpm for seven days. Following fermentation, culture supernatants were extracted with ethyl acetate (EtOAc) and evaporated under reduced pressure. In the series of feeding experiments *Streptomyces* sp. MBT27, *S. antibioticus* IMRU 3720 and *S. chrysomallus*

ATCC11523 were fermented in MM supplemented with 1% fructose and 0.7 mM anthranilamide. For the directed biosynthesis of non-natural actinomycin X halves *Streptomyces* sp. MBT27 and *S. antibioticus* IMRU 3720 were grown in MM with 1% w/v fructose, 0.7 mM anthranilamide and 0.7 mM 3-hydroxy-4-methylbenzoic acid (4-MHB) and extracted with EtOAc.

Genome sequencing, assembly and annotation

Streptomyces sp. MBT27 was grown in YEME at 30 °C and 220 rpm for 48 hours. DNA was extracted from *Streptomyces* sp. MBT27 as described (28). DNA quality was verified by agarose gel electrophoresis. PacBio sequencing and assembly was performed by Novogene (UK). Generally, library was prepared using SMRTbell template prep kit (PacBio, USA) according to manufacturer instructions. Sequencing was then performed using PacBio Sequel platform in continuous long reads mode. Assembly was done using Flye (version 2.8.1, 10.1038/s41587-019-0072-8). Biosynthetic gene clusters (BGCs) in this genome were annotated using AntiSMASH 6.0 (6). The actinomycin BGC was then extracted and compared with the same cluster from *S. antibioticus* IMRU 3720 using clinker (version 0.0.20, 10.1093/bioinformatics/btab007) with default settings.

Up-scale fermentation, extraction and fractionation

For large-scale fermentation, *Streptomyces* sp. MBT27 was grown in eight 2 L Erlenmeyer flasks, each containing 500 mL liquid MM supplemented with 2% w/v glycerol at 30 °C for seven days. The metabolites were extracted from the spun culture media using EtOAc, and the solvent was subsequently evaporated under reduced pressure at 40 °C. The crude extract (1.4 g) was adsorbed onto 1.4 g silica gel (pore size 60 Å, 70–230 mesh, Sigma Aldrich), and loaded on silica column, which was eluted using gradient mixtures of n-hexane, acetone, and MeOH. The fractions eluted with *n*-hexane–acetone (1:1) and acetone were combined, reconstituted in MeOH, and injected into preparative SunFire C₁₈ column (10 µm, 100 Å, 19 × 150 mm), which was eluted with

a H₂O–MeOH gradient of 50–100% in 20 min, at a flow rate of 15 mL/min. The fraction containing the actinomycins was collected and further purified on semi-preparative SunFire C₁₈ column (5 µm, 100 Å, 10 × 250 mm), run at 3 mL/min, and eluted using a H₂O–MeOH gradient of 70–100% in 20 min, to yield actinomycins L₁ (**1**, 2.9 mg), L₂ (**2**, 1.3 mg), X₂ (**3**, 1 mg), X_{0β} (**4**, 2.9 mg), and D (**5**, 3.2 mg),.

Actinomycin L₁ (**1**): red amorphous powder; $[\alpha]_D^{25}$ -38 (c 0.2, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 211 (1.957), 312 (0.124), 427.5 (0.152), 438 (0.151) nm; IR $\nu_{\max}$ 3301, 2963, 2921, 2859, 1740, 1662, 1644, 1585, 1521, 1465, 1405, 1300, 1262, 1191, 1097 cm⁻¹; ¹H and ¹³C NMR data, see Table 1; HRESIMS (positive mode) m/z 1387.6681 [M + H]⁺ (calcd. for C₆₉H₉₁N₁₄O₁₇, 1387.6681).

Actinomycin L₂ (**2**): red amorphous powder; $[\alpha]_D^{25}$ -54 (c 0.2, MeOH); UV (MeOH) $\lambda_{\max}$ (log ϵ) 226 (2.189), 364 (0.186) nm, 426.5 (0.367) nm; IR $\nu_{\max}$ 3308, 2943, 2929, 2831, 1748, 1662, 1644, 1585, 1448, 1406, 1302, 1262, 1191, 1113 cm⁻¹; HRESIMS (positive mode) m/z 1387.6674 [M + H]⁺ (calcd. for C₆₉H₉₁N₁₄O₁₇, 1387.6681). The X-ray diffraction experiment on a crystal grown from MeOH further confirmed the structure and determined the absolute configuration of compound **2** (Figure 4) (CCDC 2110000).

Antimicrobial activity assay and MIC determination

The antimicrobial activity of the compounds was tested in liquid inhibition assays against seven pathogens including Gram-negative and Gram-positive bacteria (*Escherichia coli* ATCC25922, *Klebsiella pneumoniae* ATCC700603, methicillin-resistant *Staphylococcus aureus* MB5393, methicillin-sensitive *Staphylococcus aureus* ATCC29213, linezolid-resistant *Staphylococcus epidermidis* (clinical isolate), vancomycin-sensitive *Enterococcus faecium* (clinical isolate), and vancomycin-resistant *Enterococcus faecium* VanB (clinical isolate), as described (1). Each compound was serially diluted in DMSO with a dilution factor of 2 to test 10 concentrations starting at 128 µg/mL in all the antimicrobial assays. The MIC was defined as the lowest concentration of

compound that inhibited $\geq 95\%$ of the growth of a microorganism after overnight incubation. The Genedata Screener software (Genedata, Inc., Basel, Switzerland) was used to process and analyze the data and to calculate the RZ' factor in the assay that was between 0.90 and 0.98 supporting its robustness.

LC-MS/MS analysis

For LC-MS analyses, extracts were dissolved in MeOH to a final concentration of 1 mg/mL, and 1 μ L was injected into Waters Acquity UPLC system equipped with Waters Acquity HSS C₁₈ column (1.8 μ m, 100 Å, 2.1 $\times$ 100 mm). For the LC, solvent A was 95% H₂O, 5% acetonitrile (ACN) and 0.1% formic acid; solvent B was 100% ACN and 0.1% formic acid. The gradient used was 2% B for 1 min, 2–85% for 9 min, 85–100% for 1 min, and 100% for 3 min. The flow rate used was 0.5 mL/min. As for the MS, the following ESI source parameters were used: capillary voltage 3 kV, source temperature 325 °C, drying gas flow rate 10 L/min, and fragmentor 175 V. Full MS spectra were acquired in positive mode in the range of 100–1700 *m/z*, in the extended dynamic range mode. Internal reference masses of purine and HP-921 (Agilent) were continuously delivered to the ESI source through an Agilent 1260 isocratic pump.

LC-MS/MS acquisition was performed using Shimadzu Nexera X2 UHPLC system coupled to Shimadzu 9030 QTOF mass spectrometer, equipped with a standard ESI source unit, in which a calibrant delivery system (CDS) is installed. The dry extracts were dissolved in MeOH to a final concentration of 1 mg/mL, and 1 μ L was injected into a Waters Acquity HSS C₁₈ column (1.8 μ m, 100 Å, 2.1 $\times$ 100 mm). The column was maintained at 40 °C, and run at a flow rate of 0.5 mL/min, using 0.1% formic acid in H₂O as solvent A, and 0.1% formic acid in acetonitrile as solvent B. A gradient was employed for chromatographic separation starting at 5% B for 1 min, then 5–85% B for 9 min, 85–100% B for 1 min, and finally held at 100% B for 4 min. All the samples were analyzed in positive polarity, using data dependent acquisition mode. In this regard, full scan MS spectra (*m/z* 100–2000, scan rate 20 Hz) were followed by three data dependent MS/MS spectra (*m/z*

100–2000, scan rate 20 Hz) for the three most intense ions per scan using collision induced dissociation (CID) with collision energy ramp (CE 20–50 eV), and excluded for 0.05 s (one MS scan) before being re-selected for fragmentation. The parameters used for the ESI source were: interface voltage 4 kV, interface temperature 300 °C, nebulizing gas flow 3 L/min, and drying gas flow 10 L/min.

LC–MS/MS acquisition for molecular networking was performed using Thermo Instruments MS system (LTQ Orbitrap XL, Bremen, Germany) equipped with an electrospray ionization source (ESI). The Waters Acquity UPLC system equipped with Waters Acquity PDA was run using a SunFire Waters C₁₈ column (3.5 µm, 100 Å, 4.6×150 mm), at a flow rate of 0.9 mL/min. Solvent A was 95% H₂O, 5% acetonitrile (ACN) and 0.1% formic acid; solvent B was 100% ACN and 0.1% formic acid. The gradient used was 2% B for 1 min, 2–85% for 15 min, 85–100% for 3 min, and 100% for 3 min. As for the MS, the following ESI parameters were used: capillary voltage 5 V, spray voltage 3.5 kV, capillary temperature 300 °C, auxiliary gas flow rate 10 arbitrary units, and sheath gas flow rate 50 arbitrary units. Full MS spectra were acquired in the Orbitrap in positive mode at a mass range of 100–2000 *m/z*, and FT resolution of 30,000. Data-dependent MS² spectra were acquired in the ion trap for the three most intense ions using collision induced dissociation (CID).

Computation of mass spectral networks

MS/MS raw data were converted to a 32-bit mzXML file using MSConvert (ProteoWizard) (8) and spectral networks were assembled using Global Natural Product Social molecular networking (GNPS) (<https://gnps.ucsd.edu>) as described (53). The precursor ion mass tolerance was set to 2.0 Da and a MS/MS fragment ion tolerance of 0.5 Da, while the minimum cosine score was set to 0.7. The data were clustered using MSCluster with a minimum cluster size of three spectra. The spectra in the network were also searched against GNPS spectral libraries. A minimum score of 0.7 was set for spectral library search, with at least six fragment peaks matching. Cytoscape 3.7.2

was used for visualization of the generated molecular networks (45). The edge thickness was set to represent the cosine score, with thicker lines indicating higher similarity between nodes. LC-MS/MS data were deposited in the MassIVE Public GNPS data set (MSV000085106). The molecular networking job in GNPS can be found at <https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=0c9153470404488d8927289139f875d3>. The annotated MS/MS spectra were deposited in the GNPS spectral library for actinomycin L₁ (CCMSLIB00005718892) and L₂ (CCMSLIB00005718891).

Statistical analysis

Prior to statistical analysis, mzXML files, which were converted using Shimadzu LabSolutions Postrun Analysis, were imported into Mzmine 2.31 (36) and processed as previously described (32). The aligned peak list was exported as a comma-separated file for statistical analysis. Statistical analysis was performed using MetaboAnalyst (9), where log transformation and pareto scaling was initially applied to the data. The normalized data were subjected to principal components analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The quality of the models was evaluated with the relevant R^2 and Q^2 . To identify the difference in intensity of a single mass feature among multiple growth conditions, one-way ANOVA was performed, followed by a *post hoc* Tukey's honest significant difference (HSD) test.

ACKNOWLEDGEMENTS

We are grateful to Victor Carrion for discussions. The work was funded by the NACTAR program of the Netherlands Organization for Scientific Research (NWO), grant nr. 16440. The authors declare no conflict of interests.

REFERENCES

1. Audoin C, Bonhomme D, Ivanisevic J, Cruz MDI, Cautain B, Monteiro MC, Reyes F, Rios L, Perez T, and Thomas OP. 2013. Balibalosides, an Original Family of Glucosylated Sesterterpenes Produced by the Mediterranean Sponge *Oscarella balibalo*. *Marine Drugs* 11:1477-1489.
2. Barka EA, Vatsa P, Sanchez L, Gavaut-Vaillant N, Jacquard C, Meier-Kolthoff J, Klenk HP, Clément C, Oudouch Y, and van Wezel GP. 2016. Taxonomy, physiology, and natural products of the Actinobacteria. *Microbiol Mol Biol Rev* 80:1-43.
3. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, and Hopwood DA. 2002. Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3(2). *Nature* 417:141-7.
4. Bérdy J. 2005. Bioactive microbial metabolites. *J Antibiot (Tokyo)* 58:1-26.
5. Biabani MA, Baake M Fau - Lovisetto B, Lovisetto B Fau - Laatsch H, Laatsch H Fau - Helmke E, Helmke E Fau - Weyland H, and Weyland H. Anthranilamides: new antimicrobial active substances from a marine *Streptomyces* sp.

6. Blin K, Shaw S, Kloosterman AM, Charlop-Powers Z, van Wezel GP, Medema MH, and Weber T. 2021. antiSMASH 6.0: improving cluster detection and comparison capabilities. *Nucleic Acids Res* 49:W29-W35.
7. Bode HB, Bethe B, Hofs R, and Zeeck A. 2002. Big effects from small changes possible ways to explore nature's chemical diversity. *ChemBioChem* 3:619-627
8. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egertson J, Hoff K, Kessner D, Tasman N, Shulman N, Frewen B, Baker TA, Brusniak MY, Paulse C, Creasy D, Flashner L, Kani K, Moulding C, Seymour SL, Nuwaysir LM, Lefebvre B, Kuhlmann F, Roark J, Rainer P, Detlev S, Hemenway T, Huhmer A, Langridge J, Connolly B, Chadick T, Holly K, Eckels J, Deutsch EW, Moritz RL, Katz JE, Agus DB, MacCoss M, Tabb DL, and Mallick P. 2012. A cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol* 30:918-20.
9. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, Wishart DS, and Xia J. 2018. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. *Nucleic Acids Res* 46:W486-W494.
10. Chong J, Yamamoto M, and Xia J. 2019. MetaboAnalystR 2.0: From Raw Spectra to Biological Insights. *Metabolites* 9.
11. Craney A, Ozimok C, Pimentel-Elardo SM, Capretta A, and Nodwell JR. 2012. Chemical perturbation of secondary metabolism demonstrates important links to primary metabolism. *Chem Biol* 19:1020-7.
12. Crnovcic I, Ruckert C, Semsary S, Lang M, Kalinowski J, and Keller U. 2017. Genetic interrelations in the actinomycin biosynthetic gene clusters of *Streptomyces antibioticus* IMRU 3720 and *Streptomyces chrysomallus*

- ATCC11523, producers of actinomycin X and actinomycin C. Adv Appl Bioinform Chem 2017:29-46.
13. Crnovčić I, Semsary S, Vater J, and Keller U. 2014. Biosynthetic rivalry of o-aminophenol-carboxylic acids initiates production of hemi-actinomycins in *Streptomyces antibioticus*. RSC Adv 4:5065-5074.
14. Cruz-Morales P, Vijgenboom E, Iruegas-Bocardo F, Girard G, Yanez-Guerra LA, Ramos-Aboites HE, Pernodet JL, Anne J, van Wezel GP, and Barona-Gomez F. 2013. The genome sequence of *Streptomyces lividans* 66 reveals a novel tRNA-dependent peptide biosynthetic system within a metal-related genomic island. Genome Biol Evol 5:1165-75.
15. Culp EJ, Waglechner N, Wang W, Fiebig-Comyn AA, Hsu YP, Koteva K, Sychantha D, Coombes BK, Van Nieuwenhze MS, Brun YV, and Wright GD. 2020. Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling. Nature 578:582-587.
16. Dalili M, and Chau PC. 1988. Production of actinomycin D with immobilized *Streptomyces parvullus* under nitrogen and carbon starvation conditions. Biotechnology Lett 10:331-336.
17. Dewick PM. 2009. Medicinal Natural Products: A Biosynthetic Approach, 3rd ed. John Wiley & Sons Ltd, Chichester.
18. Gaudencio SP, and Pereira F. 2015. Dereplication: racing to speed up the natural products discovery process. Nat Prod Rep 32:779-810.
19. Gomez-Escribano JP, Song L, Fox DJ, Yeo V, Bibb MJ, and Challis GL. 2012. Structure and biosynthesis of the unusual polyketide alkaloid coelimycin P1, a

metabolic product of the cpk gene cluster of *Streptomyces coelicolor* M145.

Chem Sci 3:2716-2720.

20. Gubbens J, Janus M, Florea BI, Overkleeft HS, and van Wezel GP. 2012.

Identification of glucose kinase dependent and independent pathways for carbon control of primary metabolism, development and antibiotic production in

Streptomyces coelicolor by quantitative proteomics. Mol Microbiol 86:1490-1507.

21. Ham Y, and Kim T-J. 2018. Anthranilamide from *Streptomyces* spp. inhibited

Xanthomonas oryzae biofilm formation without affecting cell growth. Applied Biol

Chem 61:673-680.

22. Haque SF, Sen SK, and Pal SC. 1995. Nutrient optimization for production of

broad spectrum antibiotic by *Streptomyces antibioticus* SR15.4. Acta Microbiol

Immunol Hung 42:155-162.

23. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, Sakaki Y,

Hattori M, and Omura S. 2003. Complete genome sequence and comparative

analysis of the industrial microorganism *Streptomyces avermitilis*. Nat Biotechnol

21:526-31.

24. Jones GH. 1987. Actinomycin synthesis in *Streptomyces antibioticus*: enzymatic

conversion of 3-hydroxyanthranilic acid to 4-methyl-3-hydroxyanthranilic acid. J

Bacteriol 169:5575-5578.

25. Katz E. 1967. Actinomycin, p. 276-341. In D. Gottlieb and P. D. Shaw (ed.),

Biosynthesis. Springer Berlin Heidelberg, Berlin, Heidelberg.

26. Katz E, Pienta P, and Sivak A. 1957. The role of nutrition in the synthesis of

actinomycin. Appl Microbiol 6:236–241.

27. Keller U. 1984. Acyl pentapeptide lactone synthesis in actinomycin-producing streptomycetes by feeding with structural analogs of 4-methyl-3-hydroxyanthranilic acid. *J Biol Chem* 259:8226-31.
28. Kieser T, Bibb MJ, Buttner MJ, Chater KF, and Hopwood DA. 2000. *Practical Streptomyces genetics*. John Innes Foundation, Norwich, U.K.
29. Kolter R, and van Wezel GP. 2016. Goodbye to brute force in antibiotic discovery? *Nat Microbiol* 1:15020.
30. Laatsch H. 2012. *Antibase 2012, the Natural Compound Identifier*. Wiley-VCH Verlag GmbH & Co., Weinheim, Germany.
31. Liu M, Grkovic T, Liu X, Han J, Zhang L, and Quinn RJ. 2017. A systems approach using OSMAC, Log P and NMR fingerprinting: An approach to novelty. *Synth Syst Biotechnol* 2:276-286.
32. Machushynets NV, Wu C, Elsayed SS, Hankemeier T, and van Wezel GP. 2019. Discovery of novel glycerolated quinazolinones from *Streptomyces* sp. MBT27. *J Ind Microbiol Biotechnol* 46:483-492.
33. Nett M, Ikeda H, and Moore BS. 2009. Genomic basis for natural product biosynthetic diversity in the actinomycetes. *Nat Prod Rep* 26:1362-84.
34. Nguyen DD, Wu CH, Moree WJ, Lamsa A, Medema MH, Zhao X, Gavilan RG, Aparicio M, Atencio L, Jackson C, Ballesteros J, Sanchez J, Watrous JD, Phelan VV, van de Wiel C, Kersten RD, Mehnaz S, De Mot R, Shank EA, Charusanti P, Nagarajan H, Duggan BM, Moore BS, Bandeira N, Palsson BO, Pogliano K, Gutierrez M, and Dorrestein PC. 2013. MS/MS networking guided analysis of molecule and gene cluster families. *Proc Natl Acad Sci U S A* 110:E2611-20.

35. Pfennig F, Schauwecker F, and Keller U. 1999. Molecular characterization of the genes of actinomycin synthetase I and of a 4-methyl-3-hydroxyanthranilic acid carrier protein involved in the assembly of the acylpeptide chain of actinomycin in *Streptomyces*. J Biol Chem 274:12508-12516.
36. Pluskal T, Castillo S, Villar-Briones A, and Orešič M. 2010. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11:395.
37. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, and van Wezel GP. 2008. Feast or famine: the global regulator DasR links nutrient stress to antibiotic production by *Streptomyces*. EMBO Rep 9:670-5.
38. Romano S, Jackson SA, Patry S, and Dobson ADW. 2018. Extending the "One Strain Many Compounds" (OSMAC) principle to marine microorganisms. Mar Drugs 16:244.
39. Romero-Rodriguez A, Rocha D, Ruiz-Villafan B, Guzman-Trampe S, Maldonado-Carmona N, Vazquez-Hernandez M, Zelarayan A, Rodriguez-Sanoja R, and Sanchez S. 2017. Carbon catabolite regulation in *Streptomyces*: new insights and lessons learned. World J Microbiol Biotechnol 33:162.
40. Rutledge PJ, and Challis GL. 2015. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. Nat Rev Microbiol 13:509-23.
41. Sanchez S, Chavez A, Forero A, Garcia-Huante Y, Romero A, Sanchez M, Rocha D, Sanchez B, Avalos M, Guzman-Trampe S, Rodriguez-Sanoja R, Langley E, and Ruiz B. 2010. Carbon source regulation of antibiotic production. J Antibiot (Tokyo) 63:442-59.

42. Sanchez S, and Demain AL. 2002. Metabolic regulation of fermentation processes. *Enzyme and Microbial Technology* 31:895-906.
43. Semsary S, Crnovčić I, Driller R, Vater J, Loll B, and Keller U. 2018. Ketonization of proline residues in the peptide chains of actinomycins by a 4-oxoproline synthase. *ChemBioChem* 19:706-715.
44. Shaaban KA, Shepherd MD, Ahmed TA, Nybo SE, Leggas M, and Rohr J. 2012. Pyramidamycins A-D and 3-hydroxyquinoline-2-carboxamide; cytotoxic benzamides from *Streptomyces* sp. DGC1. *J Antibiot (Tokyo)* 65:615-622.
45. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, and Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 13:2498-504.
46. Silver LL. 2011. Challenges of antibacterial discovery. *Clin Microbiol Rev* 24:71-109.
47. Theobald U, Schimana J, and Fiedler H. 2000. Microbial growth and production kinetics of *Streptomyces antibioticus* Tü 6040. *Antonie van Leeuwenhoek* 78:307–313.
48. Urem M, Swiatek-Polatynska MA, Rigali S, and van Wezel GP. 2016. Intertwining nutrient-sensory networks and the control of antibiotic production in *Streptomyces*. *Mol Microbiol* 102:183-195.
49. van Bergeijk DA, Terlouw BR, Medema MH, and van Wezel GP. 2020. Ecology and genomics of Actinobacteria: new concepts for natural product discovery. *Nat Rev Microbiol* 18:546-558.

50. van der Heul HU, Bilyk BL, McDowall KJ, Seipke RF, and van Wezel GP. 2018. Regulation of antibiotic production in Actinobacteria: new perspectives from the post-genomic era. *Nat Prod Rep* 35:575-604.
51. van Wezel GP, Konig M, Mahr K, Nothaft H, Thomae AW, Bibb M, and Titgemeyer F. 2007. A new piece of an old jigsaw: glucose kinase is activated posttranslationally in a glucose transport-dependent manner in *Streptomyces coelicolor* A3(2). *J Mol Microbiol Biotechnol* 12:67-74.
52. Waksman SA, and Woodruff HB. 1940. Bacteriostatic and Bactericidal Substances Produced by a Soil Actinomyces. *Proc Soc Exp Biol Med* 45:609-614.
53. Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, Nguyen DD, Watrous J, Kapono CA, Luzzatto-Knaan T, Porto C, Bouslimani A, Melnik AV, Meehan MJ, Liu WT, Crusemann M, Boudreau PD, Esquenazi E, Sandoval-Calderon M, Kersten RD, Pace LA, Quinn RA, Duncan KR, Hsu CC, Floros DJ, Gavilan RG, Kleigrew K, Northen T, Dutton RJ, Parrot D, Carlson EE, Aigle B, Michelsen CF, Jelsbak L, Sohlenkamp C, Pevzner P, Edlund A, McLean J, Piel J, Murphy BT, Gerwick L, Liaw CC, Yang YL, Humpf HU, Maansson M, Keyzers RA, Sims AC, Johnson AR, Sidebottom AM, Sedio BE, Klitgaard A, Larson CB, Boya PC, Torres-Mendoza D, Gonzalez DJ, Silva DB, Marques LM, Demarque DP, Pociute E, O'Neill EC, Briand E, Helfrich EJ, Granatosky EA, Glukhov E, Ryffel F, Houson H, Mohimani H, Kharbush JJ, Zeng Y, Vorholt JA, Kurita KL, Charusanti P, McPhail KL, Nielsen KF, Vuong L, Elfeki M, Traxler MF, Engene N, Koyama N, Vining OB, Baric R, Silva RR, Mascuch SJ, Tomasi S, Jenkins S, Macherla V, Hoffman T, Agarwal V, Williams PG, Dai J, Neupane R, Gurr J,

- Rodriguez AM, Lamsa A, Zhang C, Dorrestein K, Duggan BM, Almaliti J, Allard PM, Phapale P, et al. 2016. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. *Nat Biotechnol* 34:828-37.
54. Wang Q, Zhang Y, Wang M, Tan Y, Hu X, He H, Xiao C, You X, Wang Y, and Gan M. 2017. Neo-actinomycins A and B, natural actinomycins bearing the 5H-oxazolo[4,5-b]phenoxazine chromophore, from the marine-derived *Streptomyces* sp. IMB094. *Sci Rep* 7:3591.
55. Williams WK, and Katz E. 1977. Development of a Chemically Defined Medium for the Synthesis of Actinomycin D by *Streptomyces parvulus*. *Antimicrob Agents Chemother* 11:281.
56. Wright GD. 2015. Solving the Antibiotic Crisis. *ACS Infect Dis*.
57. Wu C, Choi YH, and van Wezel GP. 2016. Metabolic profiling as a tool for prioritizing antimicrobial compounds. *J Ind Microbiol Biotechnol* 43:299-312.
58. Wu C, Ichinose K, Choi YH, and van Wezel GP. 2017. Aromatic polyketide GTRI-02 is a previously unidentified product of the *act* gene cluster in *Streptomyces coelicolor* A3(2). *Chembiochem* 18:1428-1434.
59. Wu C, van der Heul HU, Melnik AV, Lubben J, Dorrestein PC, Minnaard AJ, Choi YH, and van Wezel GP. 2019. Lugdunomycin, an angucycline-derived molecule with unprecedented chemical architecture. *Angew Chem Int Ed Engl* 58:2809-2814.
60. Yoon V, and Nodwell JR. 2014. Activating secondary metabolism with stress and chemicals. *J Ind Microbiol Biotechnol* 41:415-24.

61. Zhu H, Sandiford SK, and van Wezel GP. 2014. Triggers and cues that activate antibiotic production by actinomycetes. J Ind Microbiol Biotechnol 41:371-86.
62. Zhu H, Swierstra J, Wu C, Girard G, Choi YH, van Wamel W, Sandiford SK, and van Wezel GP. 2014. Eliciting antibiotics active against the ESKAPE pathogens in a collection of actinomycetes isolated from mountain soils. Microbiology 160:1714-25.

677 **Table 1. ^1H and ^{13}C NMR data of 1 in CDCl_3 at 298 K^[a]**

Position	δ_{C} , type	δ_{H} , mult. (J in Hz)	Position	δ_{C} , type	δ_{H} , mult. (J in Hz)
1	129.5, C		22'	167.4, C	
2	130.9, C		23'	74.5, CH	5.29, qd (6.3, 3.1)
3	125.9	7.75, m	24'	17.5, CH_3	1.23, d (6.3)
4	130.0, CH	7.44, dd (7.6, 0.9)	25'	163.1, C	
5	128.5, C		26'	114.3, C	
6	140.6, C		27'	128.6, CH	7.90, dd (7.9, 1.6)
7	144.7, C		28'	118.7, CH	6.81, dt (0.9, 7.9)
8	113.6, C		29'	133.6, CH	7.30, dt (1.6, 7.9)
9	178.9, C		30'	113.9, CH	6.67, dd (7.9, 0.9)
10	ND		31'	146.7, C	
11	ND		1''	166.4, C	
12	ND		2''	55.5, CH	4.69, dd (6.6, 2.7)
13	15.1, CH_3	2.58, d (0.9)	NH-2''		7.64, d (6.6)
14	7.7, CH_3	2.26, s	3''	168.6, C	
1'	166.1, C		4''	58.6, CH	3.57, m
2'	54.7, CH	4.45, dd (6.4, 3.1)	NH-4''		7.75, m
NH-2'		7.38, d (6.4)	5''	31.8, CH	2.10, m
3'	168.7, C		6''	18.9, CH_3	1.10, d (6.7)
4'	57.9, CH	3.56, m	7''	19.2, CH_3	0.91, d (6.7)
NH-4'		8.28, d (5.4)	8''	ND	
5'	31.0, CH	2.17, m	9''	47.5, CH_2	3.82, m
					3.75, m
6'	18.8, CH_3	1.13, d (6.7)	10''	22.8, CH_2	2.29, m
					2.07, m
7'	19.1, CH_3	0.87, d (6.7)	11''	31.1, CH_2	2.84, m
					1.86, dd (11.9, 6.9)
8'	ND		12''	56.3, CH	5.95, d (9.2)
9'	60.5, CH_2	4.49, d (13.4)	13''	172.9, C	
		4.07, d (13.4)			

10'	76.8, C		14''	34.9, CH ₃	2.89, s
11'	43.1, CH ₂	2.94, m	15''	51.3, CH ₂	4.72, d (17.1)
		2.25, m			3.65, d (17.1)
12'	56.7, CH	6.27, d (10.5)	16''	165.4, C	
13'	173.1, C		17''	39.4, CH ₃	2.93, s
14'	35.1, CH ₃	2.93, s	18''	71.4, CH	2.70, m
15'	51.1, CH ₂	4.36, d (17.1)	19''	27.0, CH	2.69, m
		3.58, d (17.1)			
16'	166.3, C		20''	19.0, CH ₃	0.75, d (6.3)
17'	39.1, CH ₃	2.95, s	21''	21.7, CH ₃	0.98, d (6.0)
18'	71.3, CH	2.67, m	22''	167.2, C	
19'	26.9, CH	2.65, m	23''	75.2, CH	5.22, qd (6.3, 2.7)
20'	19.0, CH ₃	0.75, d (6.8)	24''	17.9, CH ₃	1.30, d (6.3)
21'	21.6, CH ₃	0.96, d (6.4)			

[a] ¹H 850 MHz and ¹³C NMR resonances inferred from HSQC and HMBC spectra.

Table 2. Antibacterial activities of compounds expressed as Minimal Inhibitory Concentrations (MIC)

Strain	Actinomycin X ₂	Actinomycin D	Actinomycin L ₁	Actinomycin L ₂
<i>S. aureus</i> MB5393 (methicillin-resistant)	2-4 #	1-2	4-8	8-16
<i>S. aureus</i> ATCC29213 (methicillin-sensitive)	1-2	1-2	2-4	n.a.
<i>E. faecium</i> (vancomycin-sensitive)*	1-2	1-2	4-8	8-16
<i>E. faecium</i> VanB (vancomycin-resistant)*	1-2	1-2	4-8	8-16
<i>S. epidermidis</i> *	2-4	2-4	4-8	n.a.
<i>E. coli</i> ATCC25922	>128	>128	>128	n.a
<i>K. pneumoniae</i> ATCC700603	>128	>128	>128	n.a

(*), clinical isolates; n.a.: data not available. # all concentrations given in µg/ml.

Figure Legends

Figure 1. Differential production of metabolites depending on the carbon source. A. PCA score plot of *Streptomyces* sp. MBT27 metabolites produced in cultures with different carbon sources, namely, 1% arabinose, 1% fructose, 1% GlcNAc, 1% glucose, 2% glucose, 1% glycerol, 2% glycerol, 1% mannitol, 1% mannitol + 1% glycerol and 2% mannitol (%ages in w/v). **B.** OPLS-DA score plot. Triangles and crosses represent samples of active and inactive groups respectively, circular areas represent the 95% confidence region of each group. **C.** OPLS-DA loadings S-plot. Arrows indicate the most discriminative features that positively correlate with the active groups.

Figure 2. GNPS molecular network of the ions detected in the crude extract of *Streptomyces* sp. MBT27. Cultures were grown for seven days in MM with 1% glycerol. Orange nodes represent ions of the metabolites produced by *Streptomyces* sp. MBT27, while blue nodes represent those of the media components. The actinomycin spectral family is enlarged. Results of ANOVA statistical analysis were mapped onto the molecular network to illustrate the differential production of actinomycin cluster members under various growth conditions. Box plots represent relative intensities of actinomycins X₂, X_{0β}, and D; together with a compound with an *m/z* value of 1387.67, in cultures grown in MM with the following carbon sources: 1. 1% arabinose; 2. 1% fructose; 3. 1% GlcNAc; 4. 1% glucose; 5. 2% glucose; 6. 1% glycerol; 7. 2% glycerol; 8. 1% mannitol; 9. 1% mannitol + 1% glycerol; 10. 2% mannitol (%ages in w/v).

Figure 3. Chemical structures of the new actinomycins. Shown are actinomycin L₁ (10'S) (**1**) and L₂ (10'R) (**2**) (A) and the key COSY, HMBC and NOESY correlations for **1** and **2** (B).

Figure 4. X-ray ORTEP drawing of the crystal structure of compound 2.

Figure 5. Box plots showing the relative intensities of actinomycin L₁, L₂ and X₂ and anthranilamide. Cultures of *Streptomyces* sp. MBT27 were grown for seven days in MM with the following carbon sources: 1. 1% arabinose; 2. 1% fructose; 3. 1% GlcNAc; 4. 1% glucose; 5. 2% glucose; 6. 1% glycerol; 7. 2% glycerol; 8. 1% mannitol; 9. 1% mannitol +1 % glycerol; 10. 2% mannitol (% ages in w/v). Red box indicates the abundance of actinomycin L₁, L₂ and X₂ and anthranilamide in the cultures grown with fructose (1% w/v). Note that *Streptomyces* sp. MBT27 produced actinomycin L and anthranilamide in very low amounts when fermented with fructose (1% w/v) as the sole carbon source.

Figure 6. Anthranilamide is required for the biosynthesis of actinomycins L₁ and L₂. Box plots show the relative intensities of actinomycin L₁ and L₂ in the cultures of *Streptomyces* sp. MBT27 (A) and *S. antibioticus* (B) fermented for seven days in MM with fructose (1% w/v) (1), fed with 0.7 mM anthranilamide (2) and 0.7 mM anthranilic acid (3). Note that *S. antibioticus* produces actinomycin L exclusively in the presence of anthranilamide and not with anthranilic acid; conversely, *Streptomyces* sp. MBT27 is able to convert anthranilic acid into anthranilamide, enabling the production of actinomycin L.

Figure 7. Proposed biosynthetic pathway for actinomycin L. We propose that actinomycin L is formed through the reaction of anthranilamide (blue) with the 4-oxoproline moiety of actinomycin X₂ prior to the condensation of two 4-MHA PPLs into the actinomycin L.

Supplemental Tables and Figures

Table S1. X-ray Crystallography data.

Table S2. Accurate mass of $[M+H]^+$ and product ions of the PPLs analyzed by ESI-QTOF MS/MS.

Table S3. Gene organization of the actinomycins biosynthetic gene cluster in *Streptomyces* sp. MBT27 and similarities to corresponding protein sequences encoded by orthologues in the *S. antibioticus* IMRU 3720 BGC.

Fig. S1 Antimicrobial activity of *Streptomyces* sp. MBT27 extracts against *B. subtilis*.

Fig. S2 Permutation validation of OPLS-DA model.

Fig. S3 HRMS spectrum of **1**.

Fig. S4 HRMS spectrum of **2**.

Fig. S5 ^1H NMR spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S6 ^1H - ^1H TOCSY spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S7 ^1H - ^1H COSY spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S8 HSQC spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S9 HMBC spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S10 NOESY spectrum of **1** (850 MHz, in CDCl_3 with TMS).

Fig. S11 Stacked ^1H NMR spectra of **1** and **2** (850 MHz, in CDCl_3 with TMS).

Fig. S12 UV spectrum of **1**.

Fig. S13 UV spectrum of **2**.

Fig. S14 IR spectrum of **1**.

Fig. S15 IR spectrum of **2**.

Fig. S16 *S. antibioticus* is incapable to produce actinomycin L unless anthranilamide is supplied.

Fig. S17 QTOF MS/MS spectrum of PPL 0.

Fig. S18 QTOF MS/MS spectrum of PPL 1.

Fig. S19 QTOF MS/MS spectrum of PPL 2.

Fig. S20 QTOF MS/MS spectrum of PPL 3.

757 **Fig. S21 Alignment of the actinomycin BGCs from *S. antibioticus* and *Streptomyces* sp.**
758 **MBT27.**

759

760

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7